History and evolution of the monoamine hypothesis of depression

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 6, 2000, Pages 4-6

  Hirschfeld, Robert M A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IPRONIAZID; ISONIAZID; MIRTAZAPINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NOMIFENSINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; REBOXETINE; RESERPINE; RIFAMATE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CONFERENCE PAPER; DEPRESSION; DRUG INDUCED DISEASE; HEADACHE; HUMAN; MENTAL DISEASE; NAUSEA; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; VOMITING;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG INDUSTRY; HISTORY, 20TH CENTURY; HUMANS; IMIPRAMINE; MORPHOLINES; NOREPINEPHRINE; RECEPTORS, BIOGENIC AMINE; SEROTONIN;

EID: 0034006802     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Bunney WE, Davis JM. Norepinephrine in depressive reactions. Arch Gen Psychiatry 1965;13:483-494
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of the supporting evidence. Am J Psychiatry 1965;122:509-521
3. Woolley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Science 1954;119:587-588
4. Gaddum JH. Chemical transmission in the central nervous system. Nature 1963;197:741-743
5. Muller JC, Pryer WW, Gibbons JE, et al. Depression and anxiety occurring during Rauwolfia therapy. JAMA 1955;159:836-839
6. Shore PA, Silver SL, Brodie BB. Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science 1955;122:284-285
7. Carlsson A, Lindqvist M, Magnusson T. 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957;180:1200
8. 6 on the effects of L-DOPA in man.] Klin Wochenschr 1960;38:120-123
9. Crane GE. The psychiatric side-effects of iproniazid. Am J Psychiatry 1956;112:494-501
10. Kline NS. Clinical experience with iproniazid (Marsilid). J Clin Exp Psychopathol 1961;19(suppl 1):72-78
11. Kuhn R. The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry 1958;115:459-464
12. 3-norepinephrine. J Pharmacol Exp Ther 1961;134:146-153
13. Gershon S, Homberg G, Mattsson E, et al. Imipramine hydrochloride: its effects on clinical, autonomic, and psychological functions. Arch Gen Psychiatry 1962;6:96-101
14. Glowinski J, Axelrod J. Inhibition of uptake of tritiated-noradrenaline in the intact rat brain by imipramine and structurally related compounds. Nature 1964;204:1318-1319
15. Carlsson A, Fuxe K, Ungerstedt U. The effect of imipramine on central 5-hydroxytryptamine neurons. J Pharm Pharmacol 1968;20:150-151
16. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996;16 (suppl 2):1S-9S
17. Cookson J. Side effects of antidepressants. Br J Psychiatry 1993;163:20-24
18. Carlsson A. Rationale and design of a selective inhibitor of 5-HT re-uptake. Br J Clin Pract 1982;19(suppl):19-21
19. Åberg-Wistedt A. The antidepressant effects of 5-HT uptake inhibitors. Br J Psychiatry 1989;155(suppl 8):32-40
20. Hirschfeld RMA, Schatzberg AF. Long-term management of depression. Am J Med 1994;97(suppl 6A):33S-38S
21. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997;11(suppl):S9-S15
22. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-226
23. Montgomery SA. Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 1997;7(suppl 1):S3-S9
24. Manji HK. G-proteins: implications for psychiatry. Am J Psychiatry 1992;149:746-760